Alterations of p16-pRb Pathway and Chromosome Locus 9p21–22 in Sporadic Invasive Breast Carcinomas

Table 3 Relationship of alterations at 9p21–22 chromosomal region with various clinicopathological parameters

Tumor Size (cm)					Lymph Node Metastasis			Grade				Stage					ER			PR
IHC	<2	2	>2	p	Yes	No	p	I	II	III	p	I	II	III	IV	p	P	N	p	P	N	p
MA
+	2	2	16		13	7		2	10	5		3	7	7	2		2	14		7	9
−	12	10	13	0.0091	24	11	0.7860	7	19	8	0.7149	10	17	7	2	0.3971	5	29	0.8203	11	23	0.6402
Total	14	12	29		37	18		9	29	13		13	24	14	4		7	43		18	32
LOH
+	1	2	10		9	4		1	8	3		3	3	5	2		2	8		3	7
−	13	10	19	0.1151	28	14	0.8633	8	21	10	0.9202	10	21	9	2	0.2286	5	35	0.9188	15	25	0.9413
Total	14	12	29		37	28		9	29	13		13	24	14	4		7	43		18	32
MI
+	1	0	8		6	3		1	3	3		0	4	4	1		0	8		4	4
−	13	12	21	0.0527	31	15	0.9662	8	26	10	0.5242	13	20	10	3	0.2320	7	35	0.4906	14	28	0.6183
Total	14	12	29		37	18		9	29	13		13	24	14	4		7	43		18	32

Abbreviations: MA, microsatellite alteration; LOH, loss of heterozygosity; MI, microsatellite instability; +/−, presence or absence of specified genetic alteration; ER/PR, estimation of estrogen and progesterone receptor expression, respectively; P, positive (overexpression); N, negative (normal expression).

ISSN: 1528-3658